Repro-Med Diagnostic Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.22 M
- Company Age 30 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.00 M
- Revenue Growth -15.94%
- Profit Growth -58.38%
- Ebitda -34.15%
- Net Worth 2.17%
- Total Assets 0.78%
About Repro-Med Diagnostic
Repro-Med Diagnostic Pvt. Ltd. (RDPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 June 1994 and has a history of 30 years and seven months. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.22 M.
The company currently has active open charges totaling ₹8.00 M.
Kalpa Kabir, Syed Kabir, and Rakibul Syed serve as directors at the Company.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U85195WB1994PTC063738
- Company No.
063738
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jun 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Repro-Med Diagnostic?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalpa Kabir  | Director | 28-Jun-1994 | Current |
| Syed Kabir | Additional Director | 01-Apr-2016 | Current |
| Rakibul Syed | Director | 21-Aug-2003 | Current |
Financial Performance of Repro-Med Diagnostic.
Repro-Med Diagnostic Pvt. Ltd., for the financial year ended 2020, experienced significant reduction in revenue, with a 15.94% decrease. The company also saw a substantial fall in profitability, with a 58.38% decrease in profit. The company's net worth moved up by a moderate rise of 2.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Repro-Med Diagnostic?
In 2019, Repro-Med Diagnostic had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Atgc Diagnostics Private LimitedSyed Kabir is a mutual person
Charges (Loans)
₹8.00 M
₹0
Charges Breakdown by Lending Institutions
- Housing Development Finance Corporation Limited : 0.80 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Apr 2015 | Housing Development Finance Corporation Limited | ₹8.00 M | Open |
How Many Employees Work at Repro-Med Diagnostic?
Unlock and access historical data on people associated with Repro-Med Diagnostic, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Repro-Med Diagnostic, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Repro-Med Diagnostic's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.